EFFECT OF MARAVIROC ON THE TRANSCRIPTION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) IN RESTING CD4+ T LYMPHOCYTES IN PATIENTS ON ANTIRETROVIRAL TREATMENT WITH SUPPRESSED VIRAL LOAD EFECTO DEL MARAVIROC SOBRE LA TRANSCRIPCIÓN DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA (VIH-1) EN LINFOCITOS T CD4+ EN REPOSO EN PERSONAS CON CARGA VIRAL SUPRIMIDA POR TRATAMIENTO ANTIRRETROVIRAL

Trial Profile

EFFECT OF MARAVIROC ON THE TRANSCRIPTION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) IN RESTING CD4+ T LYMPHOCYTES IN PATIENTS ON ANTIRETROVIRAL TREATMENT WITH SUPPRESSED VIRAL LOAD EFECTO DEL MARAVIROC SOBRE LA TRANSCRIPCIÓN DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA (VIH-1) EN LINFOCITOS T CD4+ EN REPOSO EN PERSONAS CON CARGA VIRAL SUPRIMIDA POR TRATAMIENTO ANTIRRETROVIRAL

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2015

At a glance

  • Drugs Maraviroc (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms MARAVITRANS
  • Most Recent Events

    • 11 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top